Time-kill determination of the bactericidal activity of telavancin and vancomycin against clinical methicillin-resistant Staphylococcus aureus isolates from cancer patients

Diagn Microbiol Infect Dis. 2017 Apr;87(4):338-342. doi: 10.1016/j.diagmicrobio.2016.12.010. Epub 2016 Dec 16.

Abstract

The bactericidal activity of vancomycin and telavancin was compared against 4 clinical methicillin-resistant Staphylococcus aureus isolates recently recovered from cancer patients, using minimum bactericidal concentration (MBC):MIC ratios and time-kill studies. All 4 isolates were susceptible to both agents based on individual MIC values. The 2 methodologies for assessing bactericidal activity produced variable results. Telavancin appeared to have somewhat better bactericidal activity than vancomycin based on narrower MBC:MIC ratios. However, based on the results of the time-kill studies, neither agent demonstrated reliable bactericidal activity (defined as a ≥3 log10 reduction of the starting inoculum at the end of 24hours) against these organisms. These findings might be of some therapeutic importance in certain clinical settings and/or specific patient populations (such as febrile neutropenic patients) in whom potent bactericidal activity is either desired or preferred.

Keywords: Bactericidal activity; Cancer patients; MRSA; Telavancin; Time-kill; Vancomycin.

MeSH terms

  • Aminoglycosides / therapeutic use*
  • Anti-Bacterial Agents / therapeutic use*
  • Humans
  • Lipoglycopeptides
  • Methicillin-Resistant Staphylococcus aureus / drug effects*
  • Methicillin-Resistant Staphylococcus aureus / isolation & purification*
  • Microbial Sensitivity Tests
  • Neoplasms / microbiology*
  • Staphylococcal Infections / drug therapy*
  • Time Factors
  • Vancomycin / therapeutic use*

Substances

  • Aminoglycosides
  • Anti-Bacterial Agents
  • Lipoglycopeptides
  • Vancomycin
  • telavancin